Form 8-K - Current report:
SEC Accession No. 0001367644-23-000082
Filing Date
2023-04-17
Accepted
2023-04-17 07:46:20
Documents
14
Period of Report
2023-04-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20230417.htm   iXBRL 8-K 32464
2 EX-99.1 emergent041723statement.htm EX-99.1 2282
6 emergent041723statement001.jpg GRAPHIC 147697
  Complete submission text file 0001367644-23-000082.txt   372633

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20230417.xsd EX-101.SCH 1965
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20230417_lab.xml EX-101.LAB 25154
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20230417_pre.xml EX-101.PRE 13100
8 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20230417_htm.xml XML 4436
Mailing Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879
Business Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 23822829
SIC: 2834 Pharmaceutical Preparations